Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells
Jazyk angličtina Země Irsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
101126/Z/13/Z
Wellcome Trust - United Kingdom
101126/Z/13/Z
Wellcome Trust - United Kingdom
PubMed
30914192
DOI
10.1016/j.tox.2019.03.009
PII: S0300-483X(18)30661-9
Knihovny.cz E-zdroje
- Klíčová slova
- Apoferritin nanoparticles, Cytochrome P450-mediated metabolism, Cytotoxicity, DNA adducts, Ellipticine, Neuroblastoma,
- MeSH
- adukty DNA genetika metabolismus MeSH
- apoferritiny chemie farmakologie MeSH
- cytochrom P-450 CYP3A metabolismus MeSH
- elipticiny chemie farmakologie MeSH
- fosforylace MeSH
- histony metabolismus MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- nanočástice * MeSH
- neuroblastom farmakoterapie enzymologie genetika patologie MeSH
- nosiče léků * MeSH
- příprava léků MeSH
- protinádorové látky chemie farmakologie MeSH
- uvolňování léčiv MeSH
- viabilita buněk účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- adukty DNA MeSH
- apoferritiny MeSH
- CYP3A4 protein, human MeSH Prohlížeč
- cytochrom P-450 CYP3A MeSH
- elipticiny MeSH
- ellipticine MeSH Prohlížeč
- H2AX protein, human MeSH Prohlížeč
- histony MeSH
- nosiče léků * MeSH
- protinádorové látky MeSH
Although ellipticine (Elli) is an efficient anticancer agent, it exerts several adverse effects. One approach to decrease the adverse effects of drugs is their encapsulation inside a suitable nanocarrier, allowing targeted delivery to tumour tissue whereas avoiding healthy cells. We constructed a nanocarrier from apoferritin (Apo) bearing ellipticine, ApoElli, and subsequently characterized. The nanocarrier exhibits a narrow size distribution suggesting its suitability for entrapping the hydrophobic ellipticine molecule. Ellipticine was released from ApoElli into the water environment under pH 6.5, but only less than 20% was released at pH 7.4. The interaction of ApoElli with microsomal membrane particles containing cytochrome P450 (CYP) biotransformation enzymes accelerated the release of ellipticine from this nanocarrier making it possible to be transferred into this membrane system even at pH 7.4 and facilitating CYP-mediated metabolism. Reactive metabolites were formed not only from free ellipticine, but also from ApoElli, and both generated covalent DNA adducts. ApoElli was toxic in UKF-NB-4 neuroblastoma cells, but showed significantly lower cytotoxicity in non-malignant fibroblast HDFn cells. Ellipticine either free or released from ApoElli was concentrated in the nuclei of neuroblastoma cells, concentrations of which being significantly higher in nuclei of UKF-NB-4 than in HDFn cells. In HDFn the higher amounts of ellipticine were sequestrated in lysosomes. The extent of ApoElli entering the nuclei in UKF-NB-4 cells was lower than that of free ellipticine and correlated with the formation of ellipticine-derived DNA adducts. Our study indicates that the ApoElli form of ellipticine seems to be a promising tool for neuroblastoma treatment.
Citace poskytuje Crossref.org
